AVANIR Pharmaceuticals to Present at Leerink Swann Inaugural Health Care Conference and Wells Fargo Securities 2005 Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Feb. 25, 2005--AVANIR Pharmaceuticals (AMEX:AVN) will be presenting at the Leerink Swann Inaugural Health Care Conference on Tuesday, March 1, 2005 at 11:00 a.m. Eastern Time in New York and at Wells Fargo Securities 2005 Healthcare Conference on Wednesday, March 2, 2005 at 3:30 p.m. Eastern Time in New York. AVANIR's President and Chief Executive Officer Dr. Gerald J. Yakatan will be presenting a corporate overview at the investor conferences.

Both presentations will be webcast live, and recordings will be made available following each presentation. The webcasts and recordings will be accessible through AVANIR's corporate website, located at www.avanir.com. For access, please log on to AVANIR's site approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

AVANIR Pharmaceuticals is a drug discovery and development company focused on treatments for chronic diseases. Our product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious disease. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect." The Company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.


    CONTACT: AVANIR Pharmaceuticals
             Patrice Saxon, 858-622-5202
             psaxon@avanir.com

    SOURCE: AVANIR Pharmaceuticals